Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/8550
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Braun, Juergen | - |
dc.contributor.author | Doedhar, Atul | - |
dc.contributor.author | Dijkmans, Ben | - |
dc.contributor.author | GEUSENS, Piet | - |
dc.contributor.author | Sieper, Joachim | - |
dc.contributor.author | Williamson, Paul | - |
dc.contributor.author | Xu, Weichun | - |
dc.contributor.author | Visvanathan, Sudha | - |
dc.contributor.author | Baker, Daniel | - |
dc.contributor.author | Goldstein, Neil | - |
dc.contributor.author | VAN DER HEIJDE, Desiree | - |
dc.date.accessioned | 2008-11-03T13:17:51Z | - |
dc.date.available | 2008-11-03T13:17:51Z | - |
dc.date.issued | 2008 | - |
dc.identifier.citation | ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 59(9). p. 1270-1278 | - |
dc.identifier.issn | 0004-3591 | - |
dc.identifier.uri | http://hdl.handle.net/1942/8550 | - |
dc.description.abstract | Objective. To assess safety and efficacy of infliximab in patients with ankylosing spondylitis (AS) through 102 weeks. Methods. Patients (n = 279) with active AS were randomized to either group 1 (n = 78; placebo through week 24 and then infliximab 5 mg/kg from weeks 24 through 96) or group 2 (n = 201; infliximab 5 mg/kg through week 96). The primary efficacy end point at week 24 (>= 20% improvement in the Assessment in Ankylosing Spondylitis International Working Group criteria [ASAS20]) was assessed with an intent-to-treat analysis of observed data. Results. More patients in group 2 than group 1 achieved the ASAS20 response at week 24 (61.2% versus 19.2%; P < 0.001). By week 102, groups 1 and 2 were similar with regard to ASAS20 response (72.1% versus 73.9%); ASAS40 responses at week 102 were 45.9% versus 59.4%. No new safety issues were discerned. Conclusion. Infliximab demonstrated sustained efficacy and safety over 2 years in this large cohort of patients with active AS. | - |
dc.language.iso | en | - |
dc.publisher | WILEY-LISS | - |
dc.title | Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 1278 | - |
dc.identifier.issue | 9 | - |
dc.identifier.spage | 1270 | - |
dc.identifier.volume | 59 | - |
local.format.pages | 9 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | [Braun, Juergen] Rheumazentrum Ruhrgebiet, D-44652 Herne, Germany. [Doedhar, Atul] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Dijkmans, Ben] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands. [Dijkmans, Ben] Jan Breemen Inst, Amsterdam, Netherlands. [Geusens, Piet] Univ Hasselt, Hasselt, Belgium. [Sieper, Joachim] Free Univ Berlin, Univ Klinikum Benjamin Franklin, D-1000 Berlin, Germany. [Williamson, Paul; Xu, Weichun; Visvanathan, Sudha; Baker, Daniel; Goldstein, Neil] Centocor Inc, Malvern, PA 19355 USA. [Van Der Heijde, Desiree] Leiden Univ, Ctr Med, Leiden, Netherlands. | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.bibliographicCitation.oldjcat | A1 | - |
dc.identifier.doi | 10.1002/art.24001 | - |
dc.identifier.isi | 000259669700010 | - |
item.fullcitation | Braun, Juergen; Doedhar, Atul; Dijkmans, Ben; GEUSENS, Piet; Sieper, Joachim; Williamson, Paul; Xu, Weichun; Visvanathan, Sudha; Baker, Daniel; Goldstein, Neil & VAN DER HEIJDE, Desiree (2008) Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. In: ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 59(9). p. 1270-1278. | - |
item.fulltext | No Fulltext | - |
item.validation | ecoom 2009 | - |
item.contributor | Braun, Juergen | - |
item.contributor | Doedhar, Atul | - |
item.contributor | Dijkmans, Ben | - |
item.contributor | GEUSENS, Piet | - |
item.contributor | Sieper, Joachim | - |
item.contributor | Williamson, Paul | - |
item.contributor | Xu, Weichun | - |
item.contributor | Visvanathan, Sudha | - |
item.contributor | Baker, Daniel | - |
item.contributor | Goldstein, Neil | - |
item.contributor | VAN DER HEIJDE, Desiree | - |
item.accessRights | Closed Access | - |
crisitem.journal.issn | 0004-3591 | - |
Appears in Collections: | Research publications |
SCOPUSTM
Citations
88
checked on Sep 3, 2020
WEB OF SCIENCETM
Citations
85
checked on May 7, 2024
Page view(s)
112
checked on Nov 7, 2023
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.